| API Access | |

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

FY2026/3 Full-Year Earnings Forecast Downward Revision

View all Renascience Inc. disclosures →

TOKYO, Mar 11 (Pulse News Wire) – Renascience Inc. (4889) has revised its FY2026/3 Full-Year earnings forecast. FORECAST REVISION SUMMARY: (Unit: ) Revenue Op Profit Ord Profit Net Profit Previous Forecast (A) 133 △380 △343 △345 Revised Forecast (B) 95 △425 △386 △387 Change (B-A) △38 △45 △42 △41 Change (%): Revenue -28.7% | OP - | OrdP - | NP - Prior Year Actual 132 △178 △178 113 KEY CHANGES: - Revenue forecast lowered by +28.7% to 95 - Net profit forecast lowered to △387 - Operating profit forecast lowered to △425 REASON FOR REVISION: Eirion Therapeutics, Inc.Ⅱ (20 ) ()Ⅲ 9 ※

Original Disclosure (PDF)

🟢 Confidence: High AI-translated content.